Global Agnosia Treatment Market: By Diagnosis (CT, MRI) Causes (Alzheimer's Disease, Pick's Disease, Melas, Balint's Syndrome) Type (Auditory Agnosia, Gustatory Agnosia, Olfactory Agnosia, Tactile Agnosia, Visual Agnosia) Treatment - Forecast till 2027
ID: MRFR/Pharma/3610-HCR | | Region: Global | 80 pages
Market Scenario
Agnosia is a rare neurological condition in which an individual may face difficulty to recognize a familiar person, sound or object. It is due to occurrence of lesions in the brain. Medical conditions such as dementia, stroke, head injury or any other neurological condition may lead to development of agnosia. Moreover, there are several conditions that may cause brain lesions and are associated with agnosia.
People suffering from agnosia can still interact with others normally. As such agnosia affects a single pathway when brain suffers a certain damage. The pathway might connect primary sensory areas that store information and knowledge. The primary sensory regions mainly include visual or auditory cortices. According to the World Health Organization (WHO) estimates, neurological disorders are responsible for 4.5%-11% of all illnesses including low or high income economies.
Brain imaging techniques such as CT or MRI with or without angiographic protocols is required to characterize a central lesion such as hemorrhage, infarct or mass and also might check medical history of the patient and atrophy suggesting a degenerative disorder.
Many individuals suffering from agnosia can still retain their cognitive abilities, such as reading and basic math. The condition affects everyone differently but it can significantly impact the quality of life.
The cause of this disorders may precede the development of primary visual agnosia. Some causes of agnosia include diseases such as Alzheimer’s, Pick’s disease, Balint’s syndrome. Alzheimer’s is a common, progressive, degenerative brain disorder affecting memory, thought, and language. Pick’s disease is also a degenerative neurological disorder that closely resemble the symptoms of Alzheimer’s disease. Balint’s syndrome is a rare neurological disorder characterized by the inability to voluntarily look at objects to the side. Individuals often cannot read, grasp or view one’s surroundings as a whole (simultanagnosia).
Some of the most probable causes of this disease are dementia, carbon monoxide poisoning, encephalitis, traumatic brain injuries and strokes. Physical examination is performed to detect any primary deficits in individual related to senses or inability to infer any test for agnosia. According to WHO, the total number of people with dementia worldwide is projected to nearly double every 20 years, to 65.7 million in 2030 and 115.4 million in 2050. The total number of new cases of dementia each year is nearly 7.7 million worldwide, implying one new case every four seconds.
There is no specific treatment for agnosia. If doctors are able to identify the cause, the treatment will be tailored to the specific problem. For example, if an abscess is causing agnosia, the doctor may prescribe antibiotics and refer for a surgery to drain the abscess. Rehabilitation with speech or occupational therapists can help patients learn to compensate for their deficits.
Organizations such as the National Institute of Neurological Disorders and Stroke (NINDS) collects and disseminates research information related to neurological disorders. Furthermore, the National Organization for Rare Disorders (NORD) has a report for patients and families about this condition. NORD is a patient advocacy organization for individuals with rare diseases and the organizations that serve them.
The global market of agnosia treatment is expected to grow at a CAGR of approximately 7.2% during the forecast period 2017-2023.
Intended Audience
- Agnosia treatment Suppliers
- Agnosia treatment Manufacturers
- Research and Development (R&D) Companies
- Medical Research Laboratories
- Academic Medical Institutes and Universities
Segmentation
The agnosia treatment market is segmented on the basis of is segmented on the basis of diagnosis, causes, type, and treatment.
On the basis of diagnosis it is segmented into Computed Tomography (CT), Magnetic Resonance Imaging (MRI), and others.
On the basis of causes it is segmented into Alzheimer's disease, Pick's disease, MELAS, Balint's syndrome.
On the basis of the type, it is segmented into auditory agnosia, gustatory agnosia, olfactory agnosia, tactile agnosia, visual agnosia, and others. Others is further segmented into prosopagnosia and anosognosia
On the basis of treatment, it is segmented into surgery, antibiotics for cerebral absess and radiation of brain tumor. Antibiotics for cerebral absess is further segmented into Ceftriaxone and Cefotaxime+metronidazole
Regional Analysis
The global agnosia treatment market consists of countries namely America, Europe, Asia Pacific, and the Middle East & Africa.
North America dominated the global agnosia treatment market owing to the increasing healthcare expenditure. The increasing incidence of accidents and brain injury is leading to development of new treatment methods are some of the driving factors responsible for the growth of the global agnosia treatment market.
Europe holds the second position in the global agnosia treatment owing to the government support for research & development and availability of funds for research. People with agnosia can benefit from speech and occupational therapy provided by the various European medical organisations such as Alzheimer Europe, and the European Conference on Visual Perception (ECVP) to learn how to deal with this impairment in their daily life.
Asia Pacific is the fastest growing agnosia treatment owing to the presence of rapidly developing healthcare technology, increasing stressful life, and high healthcare expenditure. Furthermore in the Middle East & Africa the spending for healthcare was also increased. The Middle East & Africa holds the least share of the market owing to less availability of funds, limited medical facilities, and deprived political conditions in Africa.
Key Players
Some of key the players in the global agnosia treatment market are B. Braun Melsungen (Germany), Pfizer Inc. (U.S.), Lupin ltd. (India), Fujifilm Holdings (Japan), GE Healthcare (U.S.), Siemens Healthcare(U.S.), Philips Healthcare (U.S.), F. Hoffmann-La Roche AG (Switzerland) , Aurobindo Pharma Ltd (India), Sandoz GmBH (Austria), Stellar- Bio Labs (India), Fresenius Kabi Ipsum SRL (Italy), Zhuhai United Laboratories Co Ltd (China), Cspc Zhongnuo Pharmaceutical Shijiazhuang Co Ltd (China), IPCA Labs ltd. (India) and others.
Research Methodology
Sources: Annual reports, Press release, White paper, and Company presentation
Frequently Asked Questions (FAQ) :
agnosia treatment market is projected to grow at a 7.2% CAGR between 2017-2023.
North America is projected to dominate the agnosia treatment market.
Different types of agnosia include visual agnosia, tactile agnosia, olfactory agnosia, gustatory agnosia, auditory agnosia, among others.
Some common causes of agnosia include Balint’s syndrome, Pick’s disease, and Alzheimer’s.
Eminent players profiled in the agnosia treatment market include IPCA Labs ltd. (India), Cspc Zhongnuo Pharmaceutical Shijiazhuang Co Ltd (China), Zhuhai United Laboratories Co Ltd (China), Fresenius Kabi Ipsum SRL (Italy), Stellar- Bio Labs (India), Sandoz GmBH (Austria), Aurobindo Pharma Ltd (India), F. Hoffmann-La Roche AG (Switzerland) , Philips Healthcare (U.S.), GE Healthcare (U.S.), Fujifilm Holdings (Japan), Lupin ltd. (India), Pfizer Inc. (U.S.), and B. Braun Melsungen (Germany).
TABLE OF CONTENT
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
Chapter 6. Global Agnosia Treatment Market, by Diagnosis
6.1 Introduction
6.2 Computed Tomography (CT)
6.2.1 Market Estimates & Forecast, 2020 – 2027
6.3 Magnetic Resonance Imaging (MRI)
6.3.1 Market Estimates & Forecast, 2020 – 2027
6.4 Others
6.4.1 Market Estimates & Forecast, 2020 – 2027
Chapter 7. Global Agnosia Treatment Market, by Cause
7.1 Introduction
7.2 Alzheimer's disease
7.2.1 Market Estimates & Forecast, 2020 – 2027
7.3 Pick's disease
7.3.1 Market Estimates & Forecast, 2020 – 2027
7.4 MELAS
7.4.1 Market Estimates & Forecast, 2020 – 2027
7.5 Balint's syndrome
7.5.1 Market Estimates & Forecast, 2020 – 2027
Chapter 8. Global Agnosia Treatment Market, by Type
8.1 Introduction
8.2 Auditory agnosia
8.2.1 Market Estimates & Forecast, 2020 – 2027
8.3 Gustatory agnosia
8.3.2 Market Estimates & Forecast, 2020 – 2027
8.4 Olfactory agnosia
8.4.2 Market Estimates & Forecast, 2020 – 2027
8.5 Tactile agnosia
8.5.2 Market Estimates & Forecast, 2020 – 2027
8.6 Visual agnosia
8.6.2 Market Estimates & Forecast, 2020 – 2027
8.7 Others
8.7.1 Market Estimates & Forecast, 2020 – 2027
8.7.2 Prosopagnosia
8.7.2.1 Market Estimates & Forecast, 2020 – 2027
8.7.3 Anosognosia
8.7.3.1 Market Estimates & Forecast, 2020 – 2027
Chapter 9. Global Agnosia Treatment Market, by Treatment
9.1 Introduction
9.2 Surgery
9.2.1 Market Estimates & Forecast, 2020 – 2027
9.3 Antibiotics for cerebral absess
9.3.1 Market Estimates & Forecast, 2020 – 2027
9.3.2 Ceftriaxone
9.3.2.1 Market Estimates & Forecast, 2020 – 2027
9.3.3 Cefotaxime+metronidazole
9.3.3.1 Market Estimates & Forecast, 2020 – 2027
9.4 Radiation of brain tumor
9.4.1 Market Estimates & Forecast, 2020 – 2027
Chapter .10 Global Agnosia Treatment Market, by Region
10.1 Introduction
10.2 Americas
10.2.1 North America
10.2.1.1 U.S.
10.2.1.1 Canada
10.2.2 South America
10.3 Europe
10.3.1 Western Europe
10.3.1.1 Germany
10.3.1.2 France
10.3.1.3 Italy
10.3.1.4 Spain
10.3.1.5 U.K
10.3.1.6 Rest of Western Europe
10.3.2 Eastern Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 Republic of Korea
10.4.6 Rest of Asia Pacific
10.5 The Middle East & Africa
10.5.1 United Arab Emirates
10.5.2 Saudi Arabia
10.5.3 Oman
10.5.4 Kuwait
10.5.5 Qatar
10.5.6 Rest of the Middle East & Africa
Chapter 11 Company Landscape
11.1 Introduction
11.2 Market Share Analysis
11.3 Key Development & Strategies
11.3.1 Key Developments
Chapter 12 Company Profiles
12.1 Fujifilm Holdings
12.1.1 Company Overview
12.1.2 Product Overview
12.1.3 Financials
12.1.4 SWOT Analysis
12.2 GE Healthcare
12.2.1 Company Overview
12.2.2 Product Overview
12.2.3 Financial Overview
12.2.4 Key Developments
12.2.5 SWOT Analysis
12.3 Siemens Healthcare
12.3.1 Company Overview
12.3.2 Product Overview
12.3.3 Financial Overview
12.3.4 Key Development
12.3.5 SWOT Analysis
12.4 Philips Healthcare
12.4.1 Company Overview
12.4.2 Product/Business Segment Overview
12.4.3 Financial Overview
12.4.4 Key Development
12.4.5 SWOT Analysis
12.5 B. Braun Melsungen
12.5.1 Company Overview
12.5.2 Product Overview
12.5.3 Financial overview
12.5.4 Key Developments
12.6 Pfizer Inc.
12.6.1 Company Overview
12.6.2 Product Overview
12.6.3 Financial Overview
12.6.4 Key Developments
12.7 F. Hoffmann-La Roche AG
12.7.1 Overview
12.7.2 Product Overview
12.7.3 Financials
12.7.4 Key Developments
12.7.5 SWOT Analysis
12.8 Lupin Ltd.
12.8.1 Company Overview
12.8.2 Product/Business Segment Overview
12.8.3 Financial Overview
12.8.4 Key Development
12.8.5 SWOT Analysis
12.9 Fresenius Kabi Ipsum SRL
12.9.1 Company Overview
12.9.2 Product Overview
12.9.3 Financial overview
12.9.4 Key Developments
12.10 Others
Chapter 13 MRFR Conclusion
13.1 Key Findings
13.1.1 From CEO’s View Point
13.1.2 Unmet Needs of the Market
13.2 Key Companies to Watch
13.3 Prediction of Pharmaceutical industry
Chapter 14 Appendix
LIST OF TABLES
Table 1 Agnosia Treatment Industry Synopsis, 2020 – 2027
Table 2 Agnosia Treatment Market Estimates and Forecast, 2020 – 2027, (USD Million)
Table 3 Agnosia Treatment Market by Region, 2020 – 2027, (USD Million)
Table 4 Agnosia Treatment Market by Diagnosis, 2020 – 2027, (USD Million)
Table 5 Agnosia Treatment Market by Treatment, 2020 – 2027, (USD Million)
Table 6 Agnosia Treatment Market by End Users, 2020 – 2027, (USD Million)
Table 7 North America Agnosia Treatment Market by Diagnosis, 2020 – 2027, (USD Million)
Table 8 North America Agnosia Treatment Market by Treatment, 2020 – 2027, (USD Million)
Table 9 North America Agnosia Treatment Market by End Users, 2020 – 2027, (USD Million)
Table 10 US Agnosia Treatment Market by Diagnosis, 2020 – 2027, (USD Million)
Table 11 US Agnosia Treatment Market by Treatment, 2020 – 2027, (USD Million)
Table 12 US Agnosia Treatment Market by End Users, 2020 – 2027, (USD Million)
Table 13 Canada Agnosia Treatment Market by Diagnosis, 2020 – 2027, (USD Million)
Table 14 Canada Agnosia Treatment Market by Treatment, 2020 – 2027, (USD Million)
Table 15 Canada Agnosia Treatment Market by End Users, 2020 – 2027, (USD Million)
Table 16 South America Agnosia Treatment Market by Diagnosis, 2020 – 2027, (USD Million)
Table 17 South America Agnosia Treatment Market by Treatment, 2020 – 2027, (USD Million)
Table 18 South America Agnosia Treatment Market by End Users, 2020 – 2027, (USD Million)
Table 19 Europe Agnosia Treatment Market by Diagnosis, 2020 – 2027, (USD Million)
Table 20 Europe Agnosia Treatment Market by Treatment, 2020 – 2027, (USD Million)
Table 21 Europe Agnosia Treatment Market by End Users, 2020 – 2027, (USD Million)
Table 22 Western Europe Agnosia Treatment Market by Diagnosis, 2020 – 2027, (USD Million)
Table 23 Western Europe Agnosia Treatment Market by Treatment, 2020 – 2027, (USD Million)
Table 24 Western Europe Agnosia Treatment Market by End Users, 2020 – 2027, (USD Million)
Table 25 Eastern Europe Agnosia Treatment Market by Diagnosis, 2020 – 2027, (USD Million)
Table 26 Eastern Europe Agnosia Treatment Market by Treatment, 2020 – 2027, (USD Million)
Table 27 Eastern Europe Agnosia Treatment Market by End Users, 2020 – 2027, (USD Million)
Table 28 Asia Pacific Agnosia Treatment Market by Diagnosis, 2020 – 2027, (USD Million)
Table 29 Asia Pacific Agnosia Treatment Market by Treatment, 2020 – 2027, (USD Million)
Table 30 Asia Pacific Agnosia Treatment Market by End Users, 2020 – 2027, (USD Million)
Table 31 Middle East & Africa Agnosia Treatment Market by Diagnosis, 2020 – 2027, (USD Million)
Table 32 Middle East & Africa Agnosia Treatment Market by Treatment, 2020 – 2027, (USD Million)
Table 33 Middle East & Africa Agnosia Treatment Market by End Users, 2020 – 2027, (USD Million)
LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation for Agnosia Treatment Market
Figure 3 Segmentation Market Dynamics for Agnosia Treatment Market
Figure 4 Global Agnosia Treatment Market Share, by Diagnosis 2020
Figure 5 Global Agnosia Treatment Market Share, by Treatment 2020
Figure 6 Global Agnosia Treatment Market Share, by End Users, 2020
Figure 7 Global Agnosia Treatment Market Share, by Region, 2020
Figure 8 North America Agnosia Treatment Market Share, by Country, 2020
Figure 9 Europe Agnosia Treatment Market Share, by Country, 2020
Figure 10 Asia Pacific Agnosia Treatment Market Share, by Country, 2020
Figure 11 Middle East & Africa Agnosia Treatment Market Share, by Country, 2020
Figure 12 Global Agnosia Treatment Market: Company Share Analysis, 2020 (%)
Figure 13 Fujifilm Holdings: Key Financials
Figure 14 Fujifilm Holdings: Segmental Revenue
Figure 15 Fujifilm Holdings: Geographical Revenue
Figure 16 GE Healthcare: Key Financials
Figure 17 GE Healthcare: Segmental Revenue
Figure 18 GE Healthcare: Geographical Revenue
Figure 19 Siemens Healthcare: Key Financials
Figure 20 Siemens Healthcare: Segmental Revenue
Figure 21 Siemens Healthcare: Geographical Revenue
Figure 22 Philips Healthcare: Key Financials
Figure 23 Philips Healthcare: Segmental Revenue
Figure 24 Philips Healthcare: Geographical Revenue
Figure 25 B. Braun Melsungen: Key Financials
Figure 26 B. Braun Melsungen: Segmental Revenue
Figure 27 B. Braun Melsungen: Geographical Revenue
Figure 28 Pfizer Inc.: Key Financials
Figure 29 Pfizer Inc.: Segmental Revenue
Figure 30 Pfizer Inc.: Geographical Revenue
Figure 31 F. Hoffmann-La Roche AG: Key Financials
Figure 32 F. Hoffmann-La Roche AG: Segmental Revenue
Figure 33 F. Hoffmann-La Roche AG: Geographical Revenue
Figure 34 Lupin ltd.: Key Financials
Figure 35 Lupin ltd.: Segmental Revenue
Figure 36 Lupin ltd.: Geographical Revenue
Figure 37 Fresenius Kabi Ipsum SRL: Key Financials
Figure 38 Fresenius Kabi Ipsum SRL: Segmental Revenue
Figure 39 Fresenius Kabi Ipsum SRL: Geographical Revenue
